Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)

• Laurence Peiperl,

  Affiliation University of California San Francisco, San Francisco, California, United States of America

  ⨯
• Cecilia Morgan,

  Affiliation Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

  ⨯
• Zoe Moodie,

  Affiliation Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

  ⨯
• Hongli Li,

  Affiliation Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

  ⨯
• Nina Russell,

  Affiliation Bill & Melinda Gates Foundation, Seattle, Washington, United States of America

  ⨯
• Barney S. Graham,

  Affiliation Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Georgia D. Tomaras,

  Affiliation Duke University, Durham, North Carolina, United States of America

  ⨯
• Stephen C. De Rosa,

  Affiliations Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, University of Washington, Seattle, Washington, United States of America

  ⨯
• M. Juliana McElrath ,

  * E-mail: jmcelrat@fhcrc.org

  Affiliations Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, University of Washington, Seattle, Washington, United States of America

  ⨯
• the NIAID HIV Vaccine Trials Network